speaker-icon

Latest Posts

Innoplexus-AIO-partnership

2

Jan 24

Innoplexus and AIO Studien gGmbH are jointly announcing the start of a pilot project as part of the AIO data hub initiative

January 02, 2024 - Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health...
Read More
anavex_partex_partnership_Innoplexus

27

Jun 23

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Edison_Awards_Winner

Innoplexus wins Silver Edison Award for OntosightⓇ Explore

Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary Ontosight Explore platform. The recognition comes in the category of Artificial Intelligence & User Experience. The finalists of the Edison Awards were announced on February 11th, 2020.

Ontosight Explore is a specialized life science based AI-based platform for exploring and identifying non-obvious connections between diseases, pathways, proteins/targets, and drugs. It helps to capture insights and visualize a comprehensive network of biological knowledge to better understand disease pathways and uncover novel mechanisms of action (MoA.) This expanded knowledge can drive clinical development and help to bring life saving drugs to patients.

Ontosight Explore helps a researcher understand the interconnectedness of biological systems with regard to their search term, which can be a gene, target/protein, pathway, or disease. Through aggregation of all available information, it identifies all the diseases including their associated pathways and molecular interactions which are responsible for its origin and severity. Target identification is a crucial step in drug discovery as it opens a door for new therapeutic development. Researchers can leverage Ontosight Explore to identify all known and potential pathways through which a treatment breakthrough can be achieved.

Featured News

new_app_cancer_patients

New app for cancer patients

Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…